Ginkgo Bioworks (DNA) to Release Earnings on Thursday

Ginkgo Bioworks (NYSE:DNA) is scheduled to release its earnings data after the market closes on Thursday, May 9th. Analysts expect Ginkgo Bioworks to post earnings of ($0.08) per share for the quarter. Ginkgo Bioworks has set its FY 2024 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Ginkgo Bioworks (NYSE:DNA) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The company had revenue of $34.76 million for the quarter, compared to analyst estimates of $40.37 million. Ginkgo Bioworks had a negative return on equity of 48.23% and a negative net margin of 355.08%. The firm’s revenue for the quarter was down 64.6% compared to the same quarter last year. During the same period last year, the firm earned ($0.04) EPS. On average, analysts expect Ginkgo Bioworks to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ginkgo Bioworks Trading Down 4.7 %

NYSE DNA opened at $0.94 on Wednesday. The company has a market cap of $2.03 billion, a PE ratio of -2.00 and a beta of 1.42. Ginkgo Bioworks has a 12 month low of $0.74 and a 12 month high of $2.55. The stock has a 50 day moving average of $1.06 and a 200-day moving average of $1.30.

Insider Buying and Selling at Ginkgo Bioworks

In other Ginkgo Bioworks news, insider Mark E. Dmytruk sold 47,806 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $0.84, for a total value of $40,157.04. Following the transaction, the insider now directly owns 925,400 shares of the company’s stock, valued at approximately $777,336. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Ginkgo Bioworks news, insider Mark E. Dmytruk sold 47,806 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $0.84, for a total transaction of $40,157.04. Following the transaction, the insider now owns 925,400 shares in the company, valued at approximately $777,336. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Mark E. Dmytruk sold 51,169 shares of the stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $1.05, for a total value of $53,727.45. Following the sale, the insider now directly owns 865,079 shares in the company, valued at $908,332.95. The disclosure for this sale can be found here. Insiders own 15.05% of the company’s stock.

Analyst Upgrades and Downgrades

DNA has been the topic of several recent analyst reports. TD Cowen lowered their price objective on shares of Ginkgo Bioworks from $7.00 to $3.00 and set an “outperform” rating on the stock in a research note on Friday, March 1st. The Goldman Sachs Group reduced their target price on Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating for the company in a research note on Monday, January 22nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $2.20.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.